June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Treatment Outcomes in Uveitic Macular Edema with Serous Retinal Detachment
Author Affiliations & Notes
  • Stephen Huddleston
    Ophthalmology, University of Tennessee, Memphis, TN
  • Kourtney Houser
    Ophthalmology, University of Tennessee, Memphis, TN
  • Daniel Bennett
    Ophthalmology, University of Tennessee, Memphis, TN
  • R Christopher Walton
    Ophthalmology, University of Tennessee, Memphis, TN
  • Footnotes
    Commercial Relationships Stephen Huddleston, None; Kourtney Houser, None; Daniel Bennett, None; R Christopher Walton, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2543. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stephen Huddleston, Kourtney Houser, Daniel Bennett, R Christopher Walton; Treatment Outcomes in Uveitic Macular Edema with Serous Retinal Detachment. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2543.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the outcomes of patients with uveitic macular edema with subfoveal serous retinal detachment (MESRD) to those without serous retinal detachment (ME).

Methods: Retrospective analysis of consecutive patients with uveitic macular edema treated with subtenon triamcinolone acetonide. Macular edema was defined as retinal thickness > 315 μm utilizing spectral domain optical coherence tomography (SDOCT). Serous retinal detachment was defined as the presence of fluid between the retina and the retinal pigment epithelium (RPE) as demonstrated by a hyporeflective space between the retina and RPE with SDOCT. Patients with diabetic macular edema, vitreomacular traction, epiretinal membrane, cataract surgery within 3 months of the diagnosis of macular edema, or severe inflammation preventing measurement of the retinal thickness were excluded. All patients received 1-3 subtenon triamcinolone acetonide injections at 2-3 week intervals until resolution of macular edema. Outcome measures were time to resolution of macular edema, resolution of serous retinal detachment, and cumulative number of subtenon triamcinolone acetonide injections.

Results: Thirty-seven patients with uveitic macular edema were included in the study. Twenty eyes had ME and 17 eyes had MESRD. There were no differences in age, gender, race, topical corticosteroid therapy, systemic immunosuppressive therapy, or anatomic type of uveitis between the groups. Using Kaplan Meier survival analysis, the mean time to resolution of macular edema was 6.2 weeks for the ME group and 6.1 weeks for the MESRD group. The log rank test indicated no significant difference in time to resolution of macular edema between the two groups (p=0.89). The mean number of subtenon triamcinolone acetonide injections was 1.9 and 1.6 in the ME and MESRD groups respectively (p=0.18).

Conclusions: In our sample, there was no difference in time to resolution of uveitic macular edema in patients with and without a serous retinal detachment. These results suggest that the presence of a subfoveal serous detachment does not delay the resolution of uveitic macular edema treated with subtenon triamcinolone acetonide.

Keywords: 432 autoimmune disease • 462 clinical (human) or epidemiologic studies: outcomes/complications  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×